FDCNSEFDC Limited· Pharmaceuticals & BiotechnologyHighNeutral
Announced Wed, 28 May, 2025 · 17:02 IST

FDC Limited has submitted to the Exchange, the financial results for the period ended March 31, 2025.

FDC · price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reactionminutes from the announcement price · days from the prior close
-3.4%Reaction day
₹459.55
prior close
₹445.00
announcement price
After-mkt
timing
Nifty Microcap 250market · in no size index; the smallest one is used+0.4%-3.8% vs market
Pharmaceuticals peers, median of 147sector+0.5%-3.9% vs sector

On the reaction day the stock moved 3.8 pts less than Nifty Microcap 250 and 3.9 pts less than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.

Minutes after the announcementfrom the announcement price · no benchmark
Stock
5m
-0.8
10m
-0.1
15m
+0.1
30m
-0.6
Sessions after the filingfrom the prior close
StockMarketvs marketSectorvs sector
Reaction day
-3.4+0.4-3.8+0.5-3.9
Next day
-4.5+0.7-5.2-0.2-4.3
2d
-4.6+0.7-5.3-0.3-4.3
3d
-3.8+0.5-4.3-0.4-3.4
4d
-5.3+1.0-6.3-0.1-5.2
5d
-5.6+1.5-7.1-0.1-5.5
1w
-5.0+2.8-7.8+0.5-5.5
15d
+0.3-0.7+1.0-3.0+3.3
1m
+6.2+3.7+2.5-0.2+6.4
2m
+5.8+3.0+2.8+1.2+4.6
3m
-0.9-1.4+0.5-4.2+3.3
UpDownMarket · Nifty Microcap 250Sector · Pharmaceuticals peers, median of 147Pending

Minute windows have no benchmark: there is no intraday index history to compare against.

AI summary

FDC Limited has submitted its financial results to NSE for the period ended March 31, 2025. The filing covers the company's reported earnings, income, and expense figures for the year/quarter ending March 31, 2025. The headline indicates a routine regulatory submission of audited or unaudited financial statements as required under listing rules. Detailed numbers such as revenue, profit after tax, and margins are not disclosed in the headline itself.

Likely market impact

This is a standard compliance filing and does not by itself indicate any change in business fundamentals. Shareholders should review the detailed results document to assess actual financial performance and any forward-looking commentary.